Cardiovascular diseases (CVDs) remain one of the leading causes of morbidity and mortality worldwide. Among them, angina pectoris is a common condition caused by an imbalance between oxygen demand and oxygen supply to the heart muscle. Rapid and effective relief of angina is critical for improving quality of life and preventing serious complications such as myocardial infarction.
NITROQUICK 6.4, containing Nitroglycerin 6.4 mg, is a trusted and effective anti-anginal medication. It belongs to the nitrate class of vasodilators and is specially formulated in a sustained-release (SR) form to provide longer-lasting relief and prevention of anginal attacks.
Manufactured by Steris Healthcare Pvt. Ltd., NITROQUICK 6.4 ensures high-quality, reliable, and affordable therapy for patients living with coronary artery disease (CAD) and angina.
Mechanism of Action
Nitroglycerin is a prodrug that releases nitric oxide (NO) inside vascular smooth muscle cells.
NO Activation: Stimulates guanylyl cyclase enzyme → increases cyclic GMP (cGMP).
Smooth Muscle Relaxation: Leads to vasodilation of veins, arteries, and coronary vessels.
Reduced Myocardial Oxygen Demand: Venodilation decreases preload (less blood returning to the heart).
Reduced Afterload: Arteriolar dilation lowers systemic vascular resistance, decreasing cardiac workload.
Increased Oxygen Supply: Coronary artery dilation enhances blood flow to ischemic heart regions.
The sustained-release formulation ensures a steady and prolonged effect, making it suitable for long-term angina prophylaxis.
Uses and Indications
NITROQUICK 6.4 is indicated for:
Prevention and long-term management of angina pectoris due to coronary artery disease.
Adjunct therapy in congestive heart failure (CHF): Especially when associated with myocardial ischemia.
Post-myocardial infarction: To improve oxygen delivery and reduce cardiac strain (as per physician’s guidance).
Hypertension (select cases): Sometimes used in resistant hypertension or perioperative settings.
Efficacy and Clinical Evidence
Proven Anti-Anginal Agent: Nitroglycerin has been used for over a century with robust clinical evidence supporting its role in reducing anginal episodes.
Sustained Release Advantage: SR 6.4 mg formulation provides prolonged action, reducing frequency of dosing and improving patient compliance.
Improves Exercise Tolerance: Clinical trials demonstrate increased exercise capacity and reduced angina frequency in patients on nitroglycerin SR.
Effective in CHF: Studies show improved hemodynamics in patients with congestive heart failure, reducing pulmonary congestion.
Well-Established Safety Profile: With proper use and precautions, nitroglycerin remains one of the most reliable drugs in cardiology.
Side Effects
Like all vasodilators, Nitroglycerin may cause some side effects:
Headache (common, due to vasodilation)
Dizziness or lightheadedness
Flushing of the face
Nausea or vomiting
Palpitations
Serious but rare side effects:
Severe hypotension (especially when combined with PDE-5 inhibitors like sildenafil)
Reflex tachycardia
Syncope (fainting)
Methemoglobinemia (extremely rare, in overdose cases)
Precautions
Avoid PDE-5 inhibitors (e.g., sildenafil, tadalafil): Dangerous drop in blood pressure may occur.
Blood Pressure Monitoring: Use cautiously in patients prone to hypotension.
Tolerance Development: Continuous use may reduce effectiveness. A nitrate-free interval is often recommended.
Liver or Kidney Impairment: Use with caution and adjust dosing if necessary.
Pregnancy and Lactation: Should only be used if clearly prescribed by a physician.
Driving or Machinery: May cause dizziness; avoid tasks requiring alertness.
Why Choose Steris Healthcare Pvt. Ltd.?
Uncompromised Quality: Manufactured in GMP and WHO-certified facilities.
Advanced Formulations: Sustained-release technology for long-lasting efficacy.
Affordable Care: High-quality medicines made accessible and cost-effective.
Trusted by Doctors: Widely prescribed for reliability, safety, and patient outcomes.
Commitment to Cardiac Health: Dedicated to innovation in cardiovascular and chronic disease management.
With NITROQUICK 6.4, Steris Healthcare Pvt. Ltd. delivers reliable, evidence-based therapy for patients with coronary artery disease and angina.
Conclusion
Nitroglycerin SR 6.4 mg is a clinically proven, sustained-release nitrate therapy designed for the long-term prevention of angina pectoris and management of other ischemic heart conditions. By reducing cardiac workload, improving oxygen delivery, and enhancing patient tolerance to physical activity, it plays a pivotal role in cardiovascular care.
Backed by the trusted quality of Steris Healthcare Pvt. Ltd., NITROQUICK 6.4 represents a safe, effective, and patient-friendly option in the management of chronic angina and related cardiovascular conditions.
